rabeprazole has been researched along with Chronic Disease in 14 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rabeprazole was well tolerated by both groups." | 2.69 | Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. ( Grimes, I; Hoyumpa, AM; Humphries, TJ; Trevino-Alanis, H, 1999) |
| "The rabeprazole dose was determined by the attending physician." | 1.46 | Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study. ( Furuhata, Y; Hongo, M; Ikeuchi, S; Kinoshita, Y; Kusano, M; Miyagishi, H, 2017) |
| " Examination of eradication rates according to CAM dosage revealed an eradication rate of 65." | 1.40 | Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). ( Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Kinoshita, Y | 1 |
| Hongo, M | 1 |
| Kusano, M | 1 |
| Furuhata, Y | 1 |
| Miyagishi, H | 1 |
| Ikeuchi, S | 1 |
| Takeda, N | 1 |
| Takemura, M | 1 |
| Kanemitsu, Y | 1 |
| Hijikata, H | 1 |
| Fukumitsu, K | 1 |
| Asano, T | 1 |
| Yamaba, Y | 1 |
| Suzuki, M | 2 |
| Kubota, E | 1 |
| Kamiya, T | 1 |
| Ueda, T | 1 |
| Niimi, A | 1 |
| Nykula, TD | 1 |
| Furleta, VV | 1 |
| Kawai, T | 1 |
| Takahashi, S | 1 |
| Suzuki, H | 1 |
| Sasaki, H | 1 |
| Nagahara, A | 1 |
| Asaoka, D | 1 |
| Matsuhisa, T | 1 |
| Masaoaka, T | 1 |
| Nishizawa, T | 1 |
| Ito, M | 1 |
| Kurihara, N | 1 |
| Omata, F | 1 |
| Mizuno, S | 1 |
| Torii, A | 1 |
| Kawakami, K | 1 |
| Ohkusa, T | 1 |
| Tokunaga, K | 1 |
| Mine, T | 1 |
| Sakaki, N | 1 |
| Wang, AJ | 2 |
| Liang, MJ | 2 |
| Jiang, AY | 2 |
| Lin, JK | 2 |
| Xiao, YL | 2 |
| Peng, S | 2 |
| Chen, J | 2 |
| Wen, WP | 2 |
| Chen, MH | 2 |
| Mansour, NM | 1 |
| Hashash, JG | 1 |
| El-Halabi, M | 1 |
| Ghaith, O | 1 |
| Maasri, K | 1 |
| Sukkarieh, I | 1 |
| Malli, A | 1 |
| Sharara, AI | 1 |
| Osadchuk, MA | 1 |
| Lipatova, TE | 1 |
| Chaplygin, NV | 1 |
| Sablin, OA | 1 |
| Ratnikov, VA | 1 |
| Butenko, EV | 1 |
| Pakhomova, IG | 1 |
| Starostin, BD | 1 |
| Kłopocka, M | 1 |
| Sinkiewicz, A | 1 |
| Budzyński, J | 1 |
| Pulkowski, G | 1 |
| Swiatkowski, M | 1 |
| Steward, DL | 1 |
| Wilson, KM | 1 |
| Kelly, DH | 1 |
| Patil, MS | 1 |
| Schwartzbauer, HR | 1 |
| Long, JD | 1 |
| Welge, JA | 1 |
| Livzan, MA | 1 |
| Kononov, AV | 1 |
| Mozgovoĭ, SI | 1 |
| Hoyumpa, AM | 1 |
| Trevino-Alanis, H | 1 |
| Grimes, I | 1 |
| Humphries, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis[NCT01321567] | 2,157 participants (Actual) | Observational | 2011-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for rabeprazole and Chronic Disease
| Article | Year |
|---|---|
A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; | 2011 |
7 trials available for rabeprazole and Chronic Disease
| Article | Year |
|---|---|
A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; | 2011 |
[Esophageal epithelial cells renewal in evaluation of the pariet efficacy in the treatment of patients with reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Chronic Disease; Epithel | 2002 |
[Combination therapy of chronic pancreatitis (double-blind, placebo-controlled, pilot studies)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Chronic Disease; Double-Blind Method | 2003 |
Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Chronic Disease; Female; Human | 2004 |
Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chronic Disease; Double-Blind Method; Enzym | 2004 |
[Clinical course of Helicobacter pylori associated chronic gastritis in post-eradicational period].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Di | 2007 |
Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Chronic Disease; Enzyme Inhibitors; | 1999 |
7 other studies available for rabeprazole and Chronic Disease
| Article | Year |
|---|---|
Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study.
Topics: Aged; Chronic Disease; Dose-Response Relationship, Drug; Esophagitis, Peptic; Female; Humans; Male; | 2017 |
Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough: Implications of neurogenic and neutrophilic inflammation.
Topics: Adult; Aged; Chronic Disease; Cough; Female; Gastroesophageal Reflux; Humans; Inflammation; Leukocyt | 2020 |
[Rationale for improved treatment of ulcerative disease complicated by chronic pyelonephritis].
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Diet; Female; Helicobacter In | 2013 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter I | 2014 |
Comparison of patients of chronic laryngitis with and without troublesome reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Anti-Ulcer Agents; Chronic Disease; End | 2012 |
Predictors of acid suppression success in patients with chronic laryngitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Chronic Disease; Endoscopy, Digest | 2012 |
[Clinical aspects of using pariet in treating chronic pancreatitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chronic Disease; Enzyme Inhibitors; Humans; | 2002 |